Hepatitis A virus seroprevalence and acute infection: a five-year retrospective analysis from central part of Turkey Authors: Burak Ezer, Rifat Bülbül Published: 2026 ABSTRACT AbstractBackgroundHepatitis A virus (HAV) remains an important cause of acute viral hepatitis worldwide, with its epidemiology shifting in countries undergoing socioeconomic development. In Turkey, improvements in sanitation and the introduction of routine childhood vaccination in 2012 have reduced early-life exposure, potentially creating a susceptible population among adolescents and young adults. This study aimed to evaluate current HAV seroprevalence, acute infection rates, and age-specific susceptibility patterns.MethodsThis retrospective study included individuals tested for anti-HAV IgG and IgM between January 2021 and January 2026 in a tertiary care hospital. Serological analyses were performed using chemiluminescence microparticle immunoassay. Demographic characteristics, clinical unit distributions, and temporal trends were analyzed. Statistical analyses were conducted using SPSS v22.0, with p < 0.05 considered significant.ResultsA total of 7,147 individuals were included (median age: 32 years; 57.8% female). Acute HAV infection (IgM positivity) was detected in only 0.25% of cases, with no significant differences by age or gender. Overall HAV-IgG seropositivity was 63.03%, significantly higher in adults than in children (p < 0.001). The lowest immunity was observed in adolescents aged 15–18 years (12.5%), while seropositivity peaked at 100% in individuals ≥ 60 years. A significant temporal fluctuation was noted, with seropositivity declining to 49.5% in 2022 before rising to 68.5% in 2025 (p < 0.001). Susceptibility to infection was highest among adolescents aged 15–18 years (88.6%) and young adults aged 19–30 years (60.0%).ConclusionsDespite low acute infection rates, a substantial immunity gap exists, particularly among adolescents and young adults (specifically the 15–30 age cohort). This shift reflects changing endemicity patterns and highlights the need for targeted catch-up vaccination strategies to prevent future outbreaks and severe disease in susceptible populations.Clinical trial numberNot applicable.Keywords: Hepatitis A virus, Seroprevalence, Vaccination, Disease susceptibility Background The hepatitis A virus (HAV) is a non-enveloped, single-stranded, positive-polarity RNA virus belonging to the hepatovirus genus of the picornaviridae family. It is one of the most common and important causes of acute viral hepatitis worldwide [1, 2]. This virus is primarily transmitted via the faecal-oral route through the consumption of contaminated water or food, or through direct contact with infected individuals. It continues to be a critical source of morbidity in terms of public health globally [3, 4]. The clinical course, severity and prognosis of HAV infection are directly correlated with the age at which the infection is acquired. While infection is usually asymptomatic or mildly anicteric in over 90% of cases during early childhood, infection during adolescence or adulthood can lead to jaundice, severe liver failure and, in rare cases, fatal fulminant hepatitis [1, 2]. According to statistical and epidemiological data, the mortality rate due to HAV infection is around 0.1% in individuals under 15 years of age, increasing to 2.1% in individuals over 40 years of age depending on the severity of the cellular immune response and comorbidities [2]. The endemicity level of Hepatitis A in a country or geographic region is inversely related to key public health parameters, such as per capita national income, the adequacy of infrastructure and sewerage systems, access to clean, chlorinated water sources, the level of general socioeconomic development, and community hygiene practices [3]. Turkey, which is located in a region with a high endemicity level, has shifted to the ‘medium endemicity’ category over the last twenty years thanks to significant socioeconomic improvements, the modernisation of urban infrastructure, and demographic changes brought about by migration from rural to urban areas [1, 5, 6]. However, this epidemiological shift has changed the age at which the community first becomes exposed to the virus, shifting it from childhood to adolescence and young adulthood. This has created a paradoxical public health threat: while the overall incidence of infection has decreased, there is a potential risk of an increase in the proportion of cases requiring hospitalisation and presenting with severe symptoms in the population [4, 7]. The inclusion of the Hepatitis A vaccine in the National Childhood Immunisation Programme by the Ministry of Health in late 2012 was one of the most critical and transformative turning points in HAV epidemiology in Turkey. The programme began routinely administering two doses of the inactivated virus vaccine to children born in March 2011 and later, at 18 and 24 months. This created a surge in seropositivity in the paediatric age group and significantly reduced acute infection rates in this cohort [8, 9]. However, adolescent and young adult cohorts born before 2012 were neither old enough to participate in the vaccination programme during childhood nor naturally exposed to the virus due to improved hygiene conditions, creating a completely vulnerable ‘immune gap’ for infection. This five-year retrospective study aimed to evaluate current Hepatitis A seroprevalence and acute infection rates, identify age- and gender-specific immunity gaps, and analyze temporal trends between 2021 and 2026. Ultimately, these findings intend to highlight shifting endemicity dynamics in Turkey and guide evidence-based public health interventions, particularly targeted catch-up vaccination strategies. Methods This retrospective study includes cases analysed for anti-HAV IgM and anti-HAV IgG antibodies at the Medical Microbiology Laboratory of … between January 2021 and January 2026. University Hospital. Hospital. The study protocol was approved by the Ethics Committee for Non-Drug and Medical Device Research at … University … Hospital. University (decision no.:2026/038). Hepatitis A-specific antibodies were determined using the chemiluminescence microparticle immunoassay (CMIA) method with a fully automated ARCHITECT i2000SR immunoassay analyser (Abbott Diagnostics, Abbott Park, IL, USA). The analyses used commercial ARCHITECT Anti-HAV IgM (sensitivity: 95–100%; specificity: 99–100%) and ARCHITECT Anti-HAV IgG (sensitivity: 98–100%; specificity: 99.17–100%) kits. Internal quality controls were applied in all test phases in accordance with the device specifications. When interpreting the test results, the manufacturer’s reference ranges were used. Samples with a cut-off index of ≥ 1.0 for the Anti-HAV IgG test and ≥ 1.2 for the Anti-HAV IgM test were considered positive. To exclude false positives, all samples that tested positive for HAV-IgM were reanalysed using the same method in accordance with laboratory procedures to confirm the result. HAV-IgG positivity detected in patient samples was interpreted as immunity due to natural infection or vaccination. The study flow diagram is given in Fig. 1. Study flow diagram Statistical analysis The statistical analysis of the data was performed using the SPSS (Statistical Package for the Social Sciences) v22.0 software (IBM Corp., Armonk, NY, USA). Descriptive statistics were used to express categorical variables as a number (n) and percentage (%); continuous variables (e.g. age) were expressed as median and interquartile range (IQR: 25th and 75th percentile) values according to the characteristics of the data distribution. The normality of the continuous variables’ distribution was evaluated using visual methods (histograms and Q-Q plots) and analytical methods (Kolmogorov–Smirnov and Shapiro–Wilk tests). As the data were found not to show a normal distribution, non-parametric tests were used for the analyses. The Pearson Chi-square test (or Fisher’s exact test when the expected frequencies were low) was used to compare the following categorical variables: gender; age groups; immunological profiles; and differences between clinical units. A linear-by-linear trend test was applied to examine changes in Hepatitis A (HAV-IgG) seropositivity over the years. The non-parametric Mann–Whitney U test was used to compare continuous variables between two independent groups (analysis of median age differences between seropositive and seronegative individuals). For all statistical analyses, a two-sided p-value of less than 0.05 was considered to be statistically significant. Results This retrospective study examined a total of 7,147 individuals who were assessed for hepatitis A serology. The median age of the study population was 32 years (interquartile range [IQR]: 24–44 years), and 57.76% of participants were female. Of the 5,969 individuals who underwent HAV-IgM testing to assess the presence of an acute infection, 15 (0.25%) tested positive. Of these 15 positive cases, three (20.0%) were male and 12 (80.0%) were female. One case of acute hepatitis A infection was detected in the paediatric age group (≤ 18 years), while the remaining 14 cases were adults. Examining the distribution by year, the highest number of acute cases was recorded in 2022 (n = 6). This study detected seropositivity in 63.03% of the 6,802 individuals who underwent HAV-IgG testing. Analysis of immunity status by gender revealed that HAV-IgG seropositivity was statistically significantly higher in men (68.05%) than in women (59.40%) (p < 0.001). Similarly, seropositivity was significantly higher in the adult age group than in the paediatric age group (64.45% vs. 31.76%, p < 0.001). When the detailed distribution of immunity rates according to mutually exclusive age cohorts was evaluated, seropositivity rates were found to be 89.1% in the ≤ 10 age group and 59.1% in the 11–14 age group. The lowest antibody positivity was observed in the 15–18 age group (adolescents) (12.5%). After adolescence, immunity rates progressively increased with age, reaching 37.2% in the 19–30 age group and 81.8% in the 31–59 age group. As expected, the highest immunity rate was seen in the ≥ 60 age group (100.0%) (Fig. 2). The median age of seropositive individuals (41.0) was found to be statistically significantly higher than that of seronegative individuals (25.0) (p < 0.001). Statistically significant temporal variation was observed in the overall HAV-IgG antibody positivity rate throughout the study period (p < 0.001). Overall immunity rates decreased from 61.5% in 2021 to 49.5% in 2022, before gradually increasing to reach 58.9% in 2024 and a peak of 68.5% in 2025 (Fig. 3). Hepatitis A (HAV-IgG) seropositivity rates by age cohort Yearly trend of Hepatitis A (HAV IgG) seropositivity When the clinical units from which test requests were made were evaluated, it was observed that the highest volumes of requests were made by the Occupational Health and Safety (Screening) Polyclinic (n = 3,797), the Infectious Diseases Clinic (n = 1,618) and the Internal Medicine Clinic (n = 627), respectively. Statistically significant differences in IgG seropositivity rates were observed among the clinical units (p < 0.001). The immunity rate was found to be 68.4% in the asymptomatic Occupational Health patient cohort who applied for routine pre-employment examinations and screenings. By contrast, the immunity rate was 48.5% among individuals tested in the Infectious Diseases clinic. Among patients referred from Paediatric Health and Diseases clinics, the immunity rate was 59.8% (Table 1). Table 1Distribution of Hepatitis A (HAV-IgG) immunity rates by clinical unitsClinical unit/serviceTotal tests (n)Positive (n)Seropositivity rate (%)Occupational health clinic3.7972.597%68.4%Infectious diseases1.618785%48.5Internal medicine627345%55.0Pediatrics11770%59.8 Total 6.159 3.797 *The Chi-square test was applied. A p-value < 0.05 was considered statistically significantTable Note: The table presents the top four clinical units with the highest test volumes (n=6,159). The remaining 643 tests (out of the 6,802 total) were ordered by various other minor clinics Distribution of Hepatitis A (HAV-IgG) immunity rates by clinical units *The Chi-square test was applied. A p-value < 0.05 was considered statistically significant Table Note: The table presents the top four clinical units with the highest test volumes (n=6,159). The remaining 643 tests (out of the 6,802 total) were ordered by various other minor clinics Antibody profiles were determined from a total of 5,624 individuals who underwent both HAV-IgG and HAV-IgM testing simultaneously. Unlike the overall seropositivity analysis (Fig. 2), which included all 6,802 individuals tested for HAV-IgG, this specific sub-cohort of 5,624 patients allowed us to categorize their precise immunological status into three subgroups: “Susceptible/At Risk” (IgG-/IgM-), “Naturally Immune/Vaccinated Immune” (IgG+/IgM-), and “Acute Infection” (IgM+). A statistically significant correlation was found between age group and immunological profile (susceptibility status) (p < 0.001). The highest concentration of individuals susceptible to the Hepatitis A virus was found in the childhood and young adult cohorts. A statistically significant correlation was found between age group and immunological profile (susceptibility status) (p < 0.001). The highest concentration of individuals susceptible to the Hepatitis A virus was found in the adolescent and young adult cohorts. Specifically, the susceptibility rate was 88.6% in the 15–18 age group and 60.0% in the 19–30 age group. This rate dropped to 19.2% in the 31–59 age range, with 0.6% of the population in the ≥ 60 age group found to be susceptible (Fig. 4). By contrast, the ‘immune’ profile was 11.0% in the 15–18 age group and 39.9% in the 19–30 age group, but reached 80.5% in the 31–59 age group and peaked at 99.4% in the ≥ 60 age group. The presence of acute infection was reported in less than 1% of all analysed age cohorts. When the distribution of the 6,802 HAV-IgG tests was analyzed in terms of absolute test volumes, a continuous increase was observed over the study period: 304 tests were performed in 2021, 650 in 2022, 721 in 2023, 1,283 in 2024, and a peak of 3,844 in 2025. Regarding the age distribution, the vast majority of the serological screenings were requested for the adult cohorts, specifically in the 31–59 age group (n = 3,287) and the 19–30 age group (n = 2,594). The testing volumes in the remaining cohorts were as follows: ≥60 years (n = 524), 15–18 years (n = 311), ≤ 10 years (n = 64), and 11–14 years (n = 22). Hepatitis A susceptibility and immunity profiles by age group. *Red color: susceptible (at risk), Green color: immune (past infection/ vaccinated) Discussion The low acute hepatitis A infection rate of 0.25%, as detected in our study, strongly correlates with the global trend of decreasing hepatitis A incidence, which is attributed to socioeconomic developments and vaccination programmes [10]. Reports by the World Health Organization and international epidemiological studies emphasise that access to clean water, improvements in sanitation infrastructure and rising general hygiene standards play a key role in breaking the faecal-oral transmission chain of the virus [11]. Furthermore, countries that have integrated global childhood vaccination programmes into national schedules have reported significant reductions in acute infection rates and changes in the endemic pattern of the disease [10, 12]. The low positivity rate detected in our study reflects the transition to a ‘low endemicity’ level observed in regions with a high socioeconomic development index and routine vaccination practices. Our study’s findings confirm the success of prophylactic strategies and public health interventions, aligning with the declining reports of acute hepatitis A infections in the global literature [13]. The absence of statistically significant differences in acute infection rates between age and gender groups is consistent with current international data which highlights that the classic age pattern of the disease has changed, and that a homogeneous low endemic level has been reached in the general population [12, 13]. In our study, acute Hepatitis A infection cases were most frequently detected in 2022 (n = 6), which aligns with the epidemiological fluctuations observed globally in the post-pandemic period. It is well known that the strict quarantine measures, travel restrictions and increased hand hygiene habits implemented in 2020 and 2021 dramatically reduced the incidence of faecal-oral infections worldwide [14, 15]. However, the easing of pandemic restrictions worldwide and the resumption of international travel in 2022 has led to increased re-exposure to the virus in susceptible populations [15, 16]. International surveillance data also confirm a similar rebound effect, with a significant increase in acute hepatitis cases caused by enteric viruses reported, particularly in Europe and North America, since 2022 [17]. Therefore, the acute cluster of Hepatitis A cases observed in our study in 2022 should not be considered a local fluctuation, but rather a global extension of the immunological and sociodynamic repercussions of the post-pandemic normalisation process. The HAV-IgG seropositivity rate of 63.03% detected in our study indicates that the population under study is located in the moderate region on the global epidemiological map [10]. This rate is consistent with the global downward trend in HAV infection prevalence observed in developing countries as their socioeconomic conditions, infrastructure, and hygiene standards improve [10, 18]. A key finding of our study is that seroprevalence in the paediatric age group is statistically significantly lower than in the adult cohort. Our results demonstrate a distinct U-shaped immunity curve, typical of countries in epidemiological transition. This difference is typical evidence of ‘epidemiological transmission’, showing that the age at which people are first exposed to the virus has shifted from childhood to adolescence and adulthood [19]. HAV infection is usually asymptomatic ian childhood but can lead to severe clinical conditions, including acute liver failure, in adulthood [20]. Therefore, the low seropositivity rate detected in the paediatric group indicates the formation of a growing susceptible pool. This vulnerability is most pronounced in the 15–18 age cohort, where immunity reaches its nadir at 12.5%, representing a critical gap in the community’s protection. Consequently, the risk of outbreaks within the adult age group may increase in the coming years [18, 19]. Conversely, our study revealed a significantly higher seropositivity rate among men than women. While a biological predisposition to HAV infection based on gender has not been demonstrated in the literature, this difference observed in similar epidemiological studies including the adult population is generally explained by socio-behavioural dynamics [21]. The increased social and occupational mobility of men, their exposure to communal living spaces (e.g. military bases and construction sites), and their more frequent encounters with environmental risk factors related to eating and drinking habits may be the main reasons for this statistical difference. In conclusion, our findings demonstrate that improved hygiene and sanitation practices reduce childhood infections. However, they also emphasise the urgent need to continue universal childhood vaccination programmes and catch-up vaccination programmes for at-risk adult groups, in order to eliminate the risk of this decrease in community immunity [19, 20]. A statistically significant temporal change in overall HAV-IgG antibody positivity rates was observed throughout the period covered by the study. The overall immunity rate decreased from 61.5% in 2021 to 49.5% in 2022, before gradually increasing to reach 58.9% in 2024 and a peak of 68.5% in 2025. The 61.5% immunity rate measured in 2021 represents pre-pandemic resistance resulting from the national vaccination programme established in 2012 and the natural immunity of older age groups. However, due to the cumulative effect of an unvaccinated population resulting from isolation policies implemented since spring 2020, an inability to attend primary care vaccination appointments and increasing vaccine hesitancy, the overall population positivity rate dropped to a critical level of 49.5% in 2022, with a statistical delay. This pulled the country into a dangerous medium-to-low endemicity band. Skipping the HAV doses given during infancy at 18 and 24 months increased seronegative rates in specific age cohorts and was the main cause of the overall decrease [21, 22]. Following the decline in anti-HAV IgG seropositivity in 2022, the recovery curve rose to 58.9% in 2024 and peaked at 68.5% in 2025, surpassing pre-pandemic levels. This was the result of aggressive remediation policies implemented both globally and nationally. In 2023, the WHO, UNICEF, and the Global Vaccine Alliance announced the Big Catch-Up programme, which aimed to identify and vaccinate children with zero or incomplete vaccinations. The Ministry of Health of the Republic of Turkey also launched an active vaccination campaign to identify children who had missed appointments during the pandemic via SMS and call centres using e-Nabız (the national electronic personal health record system of Turkey) Decision Support Systems, and Family Medicine Information Systems. The fact that the HAV vaccine is inactive, and that the schedule can be continued from where it left off by adhering to the six-month interval between doses, means that there is flexibility for physicians applying it in the field, and this has created the technical basis for reaching high levels of seropositivity [23]. Examining the test request profiles of clinical units reveals that the healthcare system prioritises screening and preventive medicine activities over diagnostic purposes in its approach to hepatitis A. When the total test volume is evaluated, the highest request volume is found in the Occupational Health and Safety Clinic. This was followed by the Infectious Diseases and Internal Medicine clinics, respectively. This distribution shows that routine screenings conducted at the start of working life provide the largest dataset for determining population immunity status. The statistically significant difference in IgG seropositivity rates found among clinical units is directly related to the nature of the referrals. In the ‘Occupational Health’ cohort, consisting of individuals who applied for routine pre-employment examinations and who were generally asymptomatic, the immunity rate was found to be 68.4%. By contrast, the immunity rate was lower at 48.5% among those tested in the Infectious Diseases clinic. While some of these tests might have been ordered to evaluate suspected acute infections (especially when co-tested with IgM), it is highly likely that many clinicians requested serological tests opportunistically to assess vaccination status. The lack of access to patients’ initial clinical diagnoses and symptoms limits our ability to determine the exact indication for testing in this cohort. The high immunity rate of 89.1% in the ≤ 10 age group serves as a direct indicator of the success of the national routine vaccination program initiated in 2012. However, the decline to 59.1% in the 11–14 age group highlights a transition cohort that was born just prior to the full implementation of the program. The data reveal that individuals who are susceptible (vulnerable to infection) to the virus are most prevalent in the adolescent and young adult cohorts. Our analysis showed that 88.6% of the 15–18 age group and 60.0% of the 19–30 age group remain susceptible to infection. This situation suggests that there is a large population that has lost the opportunity to acquire natural immunity due to improved sanitation, but has not yet been fully covered by the vaccination program [24]. The overall HAV-IgG seropositivity rate of 63.03% detected in our study aligns with the ‘intermediate endemicity’ status of Turkey, yet shows regional variations when compared to recent literature. Our findings are slightly lower than the 67.23% reported in a large-scale study from Istanbul and significantly lower than rates observed in Yozgat (79.1%) and Erzurum (87.3%) [4, 9]. Conversely, our seroprevalence is higher than the 58.9% reported in Samsun [25]. These regional discrepancies within the same country can be attributed to differing socioeconomic conditions, infrastructure quality, and access to clean water, which remain the primary drivers of HAV epidemiology [26]. Regarding acute infections, our HAV-IgM positivity rate of 0.25% is consistent with other reports from Turkey, such as a study in Istanbul reporting 0.13% and another nationwide analysis reporting 0.2% [4]. These low rates stand in stark contrast to high-endemicity regions like Somalia, where acute HAV infection was reported as high as 33.8% [27]. Furthermore, our observation that the highest susceptibility resides in the 15–18 (12.5% immunity) and 19–30 (37.2% immunity) age groups is mirrored in other provinces. For instance, in Izmir, seropositivity was reported as 20.8% in the 10–14 age group and 28.9% in the 15–19 age group [26]. This common ‘immunity gap’ across Turkey’s western, central, and northern regions confirms that young adults who missed both natural exposure and the 2012 vaccination program remain at significant risk. Globally, this shift toward susceptibility in older cohorts is not unique to Turkey. In the United States, recent trends show that the highest HAV infection rates have shifted from children to individuals aged 30–49 years [28]. This international trend of ‘epidemiological transition’ highlights that as hygiene improves, the risk of adult-onset outbreaks increases, necessitating the catch-up vaccination strategies we propose. Limitations of study This study has several limitations. First and foremost, its retrospective design relies exclusively on data extracted from the laboratory information system. Consequently, we lacked access to detailed clinical records, including patients’ presenting symptoms, specific clinical indications for testing, and preliminary diagnoses. This limitation precluded a deeper analysis correlating serological profiles with clinical severity. Future prospective studies integrating both serological and detailed clinical data are needed to better understand the true clinical burden of the shifting HAV epidemiology. Conclusions The shifting epidemiology of Hepatitis A in Turkey reflects the successful impact of improved sanitation and the routine childhood vaccination program introduced in 2012. However, this study clearly demonstrates the emergence of a critical ‘immunity gap,’ particularly among adolescents and young adults who missed both natural exposure and routine immunization. This highly susceptible cohort presents a significant public health risk, as acute HAV infections in adulthood are associated with greater clinical severity. To prevent future outbreaks and potential fulminant hepatitis cases, proactive public health strategies must move beyond routine childhood schedules and urgently prioritize serological screening followed by targeted catch-up vaccination programs for vulnerable young adult populations. Acknowledgements None. Abbreviations Hepatitis A virus Immunoglobulin G Immunoglobulin M Chemiluminescence microparticle immunoassay Statistical package for the social sciences Interquartile range World health organization Author contributions B.E.: conceptualization, methodology, formal analysis, investigation, resources, data curation, writing–original draft, visualization, supervision. R.B.: conceptualization, methodology, writing–review and editing. Funding This study received no financial support. Data availability The datasets used and analyzed during the current study available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The study protocol adhered to the Declaration of Helsinki and was approved by the Karatay University Non-Drug and Non-Medical Device Research Ethics Committee, acting as the Institutional Review Board (approval number: 2026/038). As this was a retrospective study, the Ethics Committee approved a waiver of informed consent. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets used and analyzed during the current study available from the corresponding author on reasonable request.